阅读说明：本技术 免疫检测中消除阿霉素干扰的方法及免疫检测试剂盒 (Method for eliminating adriamycin interference in immunoassay and immunoassay kit ) 是由 李可 张裕平 杨友 于 2018-12-06 设计创作，主要内容包括：一种免疫检测中消除阿霉素干扰的方法及免疫检测试剂盒。该方法包括：在抗阿霉素干扰剂的存在下进行免疫检测反应,其中该抗阿霉素干扰剂的终浓度为0.1mg/mL～100mg/mL,且选自由6-巯基嘌呤、6-巯基鸟嘌呤、8-杂氮鸟嘌呤、次黄嘌呤、腺嘌呤、嘌呤、2,6,8-三氧嘌呤、腺嘌呤核苷酸和腺苷所组成的组中的至少一种。该方法及试剂盒能有效消除阿霉素对免疫检测结果的干扰。(A method for eliminating adriamycin interference in immunoassay and an immunoassay kit. The method comprises the following steps: performing an immunoassay in the presence of an anti-doxorubicin interfering agent, wherein the anti-doxorubicin interfering agent has a final concentration of 0.1mg/mL to 100mg/mL and is at least one selected from the group consisting of 6-mercaptopurine, 6-mercaptoguanine, 8-azaguanine, hypoxanthine, adenine, purine, 2,6, 8-trioxypurine, adenine nucleotide and adenosine. The method and the kit can effectively eliminate the interference of the adriamycin on the result of the immunoassay.)

A method of eliminating doxorubicin interference in an immunoassay for a sample, said method comprising: performing an immunoassay in the presence of an anti-doxorubicin interfering agent, wherein the final concentration of the anti-doxorubicin interfering agent is 0.1mg/mL to 100mg/mL, and is at least one selected from the group consisting of 6-mercaptopurine, 6-mercaptoguanine, 8-azaguanine, hypoxanthine, adenine, purine, 2,6, 8-trioxypurine, adenine nucleotide and adenosine.

The method according to claim 1, wherein the final concentration of the anti-doxorubicin interfering agent is 5mg/mL to 80mg/mL, preferably 10mg/mL to 80mg/mL, more preferably 50mg/mL to 80 mg/mL.

The method according to claim 1 or 2, wherein the anti-doxorubicin interfering agent is at least one selected from the group consisting of 6-mercaptoguanine, hypoxanthine, purine and adenosine.

The method according to any one of claims 1 to 3, wherein the immunoassay is a chemiluminescent immunoassay, an electrochemiluminescent immunoassay or an enzyme-linked immunoassay, preferably an immunoassay for a tumor marker, more preferably a solid-phase immunoassay.

The method according to claims 1 to 4, wherein the anti-doxorubicin interference agent is added to the immunoassay reaction system in the form of a reagent alone, preferably in the form of a sample treatment solution, or in combination with one or more reagents, preferably the one or more reagents are selected from one or more of a substrate, a label, a solid phase coated with an immunoassay reagent, a sample treatment solution, a buffer, an ionic strength modifier, a surfactant, a preservative and a cleaning agent.

The method according to claim 5, wherein the anti-doxorubicin interference agent is added before the addition of the substrate, preferably before the addition of the solid phase coated with the immunoassay reactant or before the addition of the label, more preferably in a sample pretreatment step.

A method according to any one of claims 1 to 6, wherein the sample is a blood sample, such as a serum sample or a plasma sample.

An immunoassay kit, the kit comprises an anti-doxorubicin interference agent with a final concentration of 0.1-100 mg/mL, and the doxorubicin interference agent is at least one selected from the group consisting of 6-mercaptopurine, 6-mercaptoguanine, 8-azaguanine, hypoxanthine, adenine, purine, 2,6, 8-trioxypurine, adenine nucleotide and adenosine.

The immunoassay kit according to claim 8, wherein the immunoassay kit comprises an anti-doxorubicin interfering agent at a final concentration of 5mg/mL to 80mg/mL, preferably 10mg/mL to 80mg/mL, more preferably 50mg/mL to 80 mg/mL.

The immunoassay kit according to claim 8 or 9, wherein the anti-doxorubicin interfering agent is at least one selected from the group consisting of 6-mercaptoguanine, hypoxanthine, purine and adenosine.

The immunoassay kit according to any one of claims 8 to 10, wherein the immunoassay kit is a chemiluminescent immunoassay kit, an electrochemiluminescent immunoassay kit or an enzyme-linked immunoassay kit, preferably a tumor marker immunoassay kit.

The immunoassay kit of any one of claims 8 to 11, wherein the anti-doxorubicin interference agent is contained in the immunoassay kit in combination with one or more reagents of the kit, or in the form of a separate reagent.

The immunoassay kit of claim 11 or 12, wherein the immunoassay kit further comprises a substrate, a label and a solid phase coated with an immunoassay reactant, and optionally one or more selected from the group consisting of a sample treatment solution, a buffer solution, an ionic strength modifier, a surfactant and a preservative.

An immunoassay kit according to any of claims 8 to 13, wherein the immunoassay kit is for the detection of a blood sample, such as a serum sample or a plasma sample.

Use of an anti-doxorubicin interfering agent selected from at least one of the group consisting of 6-mercaptopurine, 6-mercaptoguanine, 8-azaguanine, hypoxanthine, adenine, purine, 2,6, 8-trioxypurine, adenine nucleotide and adenosine in the elimination of doxorubicin interference in the immunoassay of a blood sample.